Here are the 10-Q quarterly reports from Vogenx Inc (VOGX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VOGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOGX filings page.
Vogenx, Inc. (VOGX), a clinical-stage drug developer, reported a net loss of $4,907,603 for the three months ended September 30, 2026, compared with $284,407 a year earlier; nine-month net loss was $5,767,485 versus $935,823. The company has not generated product-sales revenue. Quarterly research and development expense was $1,079,000, including $714,422 in direct post-bariatric hypoglycemia program costs, primarily startup costs for the EMERGE Phase 2b study. A $3.4 million non-cash warrant remeasurement loss contributed to other expense.
The August 2026 IPO generated approximately $84.4 million in net proceeds. Cash, cash equivalents and marketable securities totaled $82.1 million at September 30, 2026. Management expects these resources to fund operations and obligations for at least 12 months from the financial statements’ issuance and concluded substantial doubt about going concern did not exist. The company expects substantial operating losses to continue. Management found disclosure controls ineffective at a reasonable assurance level due to material weaknesses in internal controls over financial reporting and began a remediation risk assessment.
Vogenx, Inc. (VOGX), a clinical-stage biotech focused on mizagliflozin for serious metabolic and gastrointestinal diseases, reported a larger net loss and a significant cash burn for the quarter and six months ended June 30, 2026. Net loss was $384,430 for the quarter and $859,882 for six months, up from $294,797 and $651,416 a year earlier, driven by higher research and development and general and administrative expenses.
At June 30, 2026, Vogenx had $193,017 of cash and cash equivalents, $3.19 million in total liabilities and a stockholders’ deficit of $1.78 million, with an accumulated deficit of $11.7 million. However, in August 2026 the company completed its IPO, issuing 7,187,500 shares at $13.00 per share and receiving approximately $84.9 million in net proceeds, plus automatic conversion of preferred stock, convertible notes and warrants into common stock. Management now believes available cash, including IPO proceeds, will fund operations for at least 12 months and expects funding through 2028, though substantial additional capital will be needed before any Phase 3 trials. A one-for-three reverse stock split became effective July 28, 2026, and disclosure controls were deemed ineffective due to previously identified material weaknesses in internal control over financial reporting.